Verastem - Turnaroundspekulation 2016


Seite 1 von 11
Neuester Beitrag: 19.01.24 13:08
Eröffnet am:01.04.16 12:26von: Balu4uAnzahl Beiträge:252
Neuester Beitrag:19.01.24 13:08von: VassagoLeser gesamt:82.728
Forum:Hot-Stocks Leser heute:10
Bewertet mit:
2


 
Seite: < 1 | 2 | 3 | 4 |
8 | 9 | 10 | 11 11  >  

23475 Postings, 5104 Tage Balu4uVerastem - Turnaroundspekulation 2016

 
  
    #1
2
01.04.16 12:26

Mal sehen, was bei dem Kurs / Kursverlauf alles passieren kann!

Pipeline:

http://www.verastem.com/products/

Aktueller Kurs: 1,58  +0,15  +10,49 %  in USD
 
226 Postings ausgeblendet.
Seite: < 1 | 2 | 3 | 4 |
8 | 9 | 10 | 11 11  >  

2309 Postings, 1840 Tage BananiLäuft,

 
  
    #228
09.06.21 16:32
schön langsam und stetig!  

2309 Postings, 1840 Tage BananiNews

 
  
    #229
20.09.21 13:31
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

https://www.businesswire.com/news/home/20210920005200/en/  

2309 Postings, 1840 Tage BananiWeitere News

 
  
    #230
20.09.21 13:33
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

•Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.

•11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.

•Combination continues to exhibit a favorable tolerability profile.

•Top-line results from the selection portion of Verastem’s registration-directed Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.

https://finance.yahoo.com/news/...updated-investigator-153000366.html  

11554 Postings, 2481 Tage VassagoVSTM 2.29$

 
  
    #231
1
23.12.21 18:50
Einige Insiderverkäufe in den letzten Tagen! Steckt mehr dahinter?
https://investor.verastem.com/financial-information/sec-filings  

2309 Postings, 1840 Tage BananiVassago

 
  
    #232
23.12.21 19:55
Danke für Hinweis!
Wird langsam Zeit das der Zug hier ins Rollen kommt.  

2309 Postings, 1840 Tage BananiInstitutional Activity

 
  
    #233
18.01.22 06:29
1/06/2022 BVF PARTNERS LP  Bought 3.5 Million shares of Verastem Inc


https://money.cnn.com/quote/quote.html?symb=VSTM  

11554 Postings, 2481 Tage VassagoVSTM 1.68$ (neues 52WT)

 
  
    #234
18.01.22 20:17
MK 305 Mio. $, operative Ausgaben pro Quartal ~15 Mio. $. Cashbestand von 103 Mio. $ soll bis 2024 reichen. Nehme ich mal in Beobachtung.
https://investor.verastem.com/news-releases/...2021-financial-results  

11554 Postings, 2481 Tage VassagoVSTM 1.14$ (neues 52 WT)

 
  
    #235
24.02.22 16:25
Mk 208 Mio. $, bei 0,60$ denke ich über einen Einstieg nach  

11554 Postings, 2481 Tage VassagoVSTM 1.24$

 
  
    #236
2
28.03.22 16:34

Zahlen für Q4/21

  • Umsatz 0,5 Mio. $
  • Verlust 16,5 Mio. $
  • Cash 100 Mio. $
  • MK 234 Mio. $

-  Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC;

- Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib

- Enrollment Complete in Selection Phase (Part A) of RAMP 201 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer; Expect to Report Results from Part A in 2Q 2022

- Enrollment Complete in Selection Phase (Part A) of RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of KRAS G12V Mutant Non-Small Cell Lung Cancer; Expect to Report Results from Part A in 2H 2022

https://investor.verastem.com/news-releases/...ter-and-full-year-2021

Durch das Funding mit Oxford wird VSTM wieder interessanter, beobachte ich weiter, Alert bei 1,00$

 

2309 Postings, 1840 Tage BananiHeftiger Anstieg

 
  
    #237
1
14.04.22 18:36

2309 Postings, 1840 Tage BananiPrice Target of $5

 
  
    #238
1
15.04.22 19:35
RBC Capital Initiates Coverage On Verastem with Outperform Rating, Announces Price Target of $5

https://www.benzinga.com/news/22/04/26628716/...ces-price-target-of-5
 

11554 Postings, 2481 Tage VassagoVSTM 1.04$

 
  
    #239
1
16.05.22 18:37
MK 194 Mio. $, bei Cash+Finanzierung = 250 Mio. $, dazu eine gute Reichweite und noch ein paar Katalysatoren in 2022  

1344 Postings, 3212 Tage oli25Chart

 
  
    #240
1
18.07.22 09:03
auch das Chartbild lädt aktuell meiner Meinung nach wieder zum Einstieg ein.
Sieht sehr vielversprechend aus, wenn der Newsflow positiv bleibt.  

11554 Postings, 2481 Tage VassagoVSTM 0.92$

 
  
    #241
2
27.09.22 11:33

Zahlen für Q2/22

  • keine Umsätze
  • Verlust 22 Mio. $
  • Cash 94 Mio. $
  • MK 173 Mio. $

- expects that it has a cash runway until at least 2025

https://investor.verastem.com/news-releases/...2022-financial-results

 

11554 Postings, 2481 Tage VassagoVSTM 0.71$ (vorbörslich -19%)

 
  
    #242
04.10.22 15:26

Update

- Results of Part A of RAMP 202 Trial in KRAS G12V-Mutant NSCLC Show VS-6766 ± Defactinib Did Not Meet Criteria to Continue to Expansion Phase

https://investor.verastem.com/news-releases/...66-clinical-trials-and

 

11554 Postings, 2481 Tage VassagoVSTM 0.57$ (-35%)

 
  
    #243
05.10.22 10:23
Heftiger Ausverkauf gestern, aber dieser bietet auch Chancen.  

11554 Postings, 2481 Tage VassagoVSTM 0.45$ (neues 52 WT)

 
  
    #244
12.10.22 12:56
Die MK liegt aktuell bei ca. 95 Mio. $, dass entspricht in etwa dem Q2-Cashbestand.  

11554 Postings, 2481 Tage VassagoVSTM 0.415$

 
  
    #245
28.03.23 12:40

Zahlen für Q4/22

  • keine Umsätze
  • Verlust 17 Mio. $
  • Cash 88 Mio. $
  • MK 83 Mio. $

https://investor.verastem.com/news-releases/...ter-and-full-year-2022

 

11554 Postings, 2481 Tage VassagoVSTM 0.401$

 
  
    #246
1
18.05.23 09:56

Zahlen für Q1/23

  • kein Umsatz
  • Verlust 16 Mio. $
  • Cash 111 Mio. $
  • MK 81 Mio. $

https://investor.verastem.com/news-releases/...2023-financial-results

 

2309 Postings, 1840 Tage BananiLäuft

 
  
    #247
26.05.23 18:57
In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.

https://finance.yahoo.com/news/...t-verastem-oncologys-210500253.html  

2309 Postings, 1840 Tage Banani1-for-12 reverse stock split

 
  
    #248
31.05.23 22:15
the reverse stock split will become effective at 5:00 p.m. Eastern Time on May 31, 2023 (the "Effective Time") and the Company expects that its common stock will open for trading on June 1, 2023 on the Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trading symbol "VSTM".

https://finance.yahoo.com/news/...ounces-reverse-stock-131100164.html

Trotz einer solchen Meldung ein verdammt starker bzw. stabiler Kursverlauf.
 

11554 Postings, 2481 Tage VassagoVSTM 1.02$

 
  
    #249
01.06.23 12:27

2309 Postings, 1840 Tage Bananiwww.theguardian.com

 
  
    #250
2
04.06.23 11:11
New drug combination offers ovarian cancer breakthrough

...The revolutionary treatment has been shown to significantly shrink tumours in almost half of patients with the disease

...The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the “fantastic” and “very exciting” results from clinical trials of the drug combination, presented at the world’s largest cancer conference this weekend, showed it was “far more effective” than any available option for patients.

...The phase 2 trial, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, tested the drug avutometinib alone and in combination with defactinib in 29 patients.

Trial results show almost half the patients on the new drug combination – 45% – saw their tumours shrink significantly. It proved to be almost twice as effective as the next best treatment – trametinib, which has a response rate of 26%.

https://www.theguardian.com/science/2023/jun/03/...ancer-breakthrough  

11554 Postings, 2481 Tage VassagoVSTM 9.90$ (vorbörslich -9%)

 
  
    #251
16.06.23 13:59

85 Mio. $ Offering

  • u.a. 7,18 Mio. neue Aktien zu je 9,75$

Verastem Oncology beabsichtigt, den Nettoerlös aus dem öffentlichen Angebot für:

  • (i) die fortgesetzte Forschung und Entwicklung seiner Produktkandidaten
  • (ii) die potenzielle Einführung von avutometinib und defactinib bei niedriggradigem serösem Eierstockkrebs und 
  • (iii) das Betriebskapital und andere allgemeine Unternehmenszwecke zu verwenden

https://investor.verastem.com/news-releases/...illion-public-offering

 

11554 Postings, 2481 Tage VassagoVSTM 10.39$

 
  
    #252
1
19.01.24 13:08
  • FDA gewährt Fast-Track-Benennung für die Kombination von Avutometinib und Sotorasib zur Behandlung von KRAS G12C-Mutant NSCLC

https://investor.verastem.com/news-releases/...esignation-combination

 

Seite: < 1 | 2 | 3 | 4 |
8 | 9 | 10 | 11 11  >  
   Antwort einfügen - nach oben